Schweitzer M.E., Gannon F.H., Deely D.M., O'Hara B.J., Juneja V.
Percutaneous
skeletal aspiration and core biopsy: complementary techniques // A.J.R. Am. J.
Roentgenol. — 1996. — V. 166(2). — P 415 418.
Sciuto R., Maini C.L., Tofani A., Fiumara C., Scelsa M.G., Broccatelli M.
Radiosensitization with low dose carboplatin enhances pain palliation in radioisotope
therapy with strontium 89 // Nucl. Med. Commun. — 1996. — V. 17(9). — P. 799 804.
Secreto G., Recchione C., Cavalerri A.
Circulating levels of testosterone, 17 ( oestra
diol, lateinising hormone and prolactin in postmenopausal breast cancer patients // Brit. J.
of Cancer. — 1983. — V. 47(2). — P.269 275.
Seidman A.D., Norton L., Riechman B.S.,
è ñîàâò. Preliminary experience wirh
paclitaxel (Taxol) plus recombinant human granulocyte colony stimulating factor in the
treatment of breast cancer // Semin. Oncol. — 1993. — V. 20. — P. 40 45.
Seidman A.D., Riechman B.S., Crown J.P.
è ñîàâò. Paclitaxel as second and subse
quent therapy for metastatic breast cancer: Activity independent of prior antracycline
response // J. Clin. Oncol. — 1995. — V. 13. — P. 1152 1159.
Seidman A.D., Hudis C.A., Albanel J.,
è ñîàâò. Dose dense therapy with weekly
1 hour paclitaxel infusions in the treatment of metastatic breast cancer // J. Clin. Oncol. —
1998. — V. 16. — P. 3353 3361.
Seki T., Sasamoto H., Yamaji T.
Efficacy of etoposide in bone metastasis of breast
cancer // Gan. To Kagaku Ruoho. — 1989. — V. 16(2). — P. 273 276.
Serafini A.N.
Current status of systemic intravenous radiopharmaceuticals for the
treatment of painful metastatic bone disease // Int .J. Radiat. Oncol. Biol. Phys. — 1994. —
V. 30(5). — P. 1187 1194.
Sharp J.G., Mann S.L., De Boer J.
åt al. Long term culture as a method of detectoin
of occult tumor cells in bone marrow and blood // J. In Vitro Cell Develop Biol. — 25:
Meeting abstract. — 1989. —¹ 105.
Sherman L.M.
The use of sustained — releas morphine in a hospis setting //
Pharmatherapeutica. — 1987. — V.5(2). — P. 99 102.
Shigematsu N., Ito H., Toya K.
Palliative radiotherapy for symptomatic osseus
metastases // Nippon. Igaru. Hoshasen Gakkai Zasshi. — 1995. — V. 55 (9). — P.677 681.
Shimozuma K., Sonoo H., Fukunaga M., Ichihara K., Aoyama T., Tanaka K.
Biochemical markers of bone turnover in breast cancer patients with bone metastases: a
preliminary report // Jpn. J. Clin. Oncol. — 1999. — V. 29(1). — P. 16 22.
Shinozaki T., Chifira M.
Diagnosis of skeletal metastases by serum tumor markers //
Nippon. Seikeigera Gakkai Zasshi. — 1991. — V. 65 (8). — P.441 446.
Silberstein T.B.
The treatment of painful osseous metastases with phosphorus 32
labeled phosphates // Semin. Oncol. — 1993. — V. 20 (Suppl. 2). — P. 10 21.
Singer F.R., Ritch P.S., Lad T.E.
è ñîàâò. Treatment of hypercalcemia of malignan
cy with intravenous etidronate. A controlled, multicenter study // Arch Intern. Med. —
1991. — V. 151 — P. 471 476.
Singhakowinto A., Saunders D.E., Brooks S.C., Samal B., Vaitkevicius V.K.
Clinical
application of oestrogen receptor in breast cancer // Cancer. — 1980. — V. 46. — P. 2932
2938.
Siwek B., Lacroix M., de Pollak C.,
è ñîàâò. Secretory products of breast cancer cells
affect human osteoblastic cells: Partial characterization of active factors // J. Bone Miner.
Res. — 1997. — V. 12. — P. 552 560.
Skrabanek P., McPartlin D., Powell D.M.
Tumor hypercalcaemia and ectopic hyper
parathyroidism // Medicine. — 1980. — V. 59. — P. 262 282.
247
Êîñòíûå ìåòàñòàçû ðàêà ìîëî÷íîé æåëåçû
